Turn Therapeutics Inc. (TTRX) Investor Relations Documents

Turn Therapeutics Inc. (TTRX) investor relations documents from the company's IR site: 3 presentations, 19 press releases; latest deck 2026-07-27. Read in-app with summaries. First-party data.

Corporate Presentation: Turn Therapeutics is a biotechnology company developing GX-03, a non-systemic topical therapy for atopic dermatitis, with Phase 2 topline results due Q4 2026.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-20	Press release	Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammatio
2026-08-12	Press release	Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
2026-07-28	Press release	Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
2026-07-27	Presentation	Corporate Presentation
2026-07-07	Press release	Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
2026-07-07	Presentation	TTRX - 7.7.2026 - Webcast Presentation Deck.pdf
2026-07-06	Press release	Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in At
2026-06-03	Presentation	Jefferies Global Healthcare Conference 2026 Presentation
2026-06-01	Press release	Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moder
2026-05-27	Press release	Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity
2026-05-19	Press release	Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
2026-05-18	Press release	Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical a
2026-05-11	Press release	Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-03-31	Press release	Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-24	Press release	Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
2026-02-09	Press release	Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
2026-01-12	Press release	Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthc
	Press release	Turn Therapeutics Intranasal Vaccine Candidate Demonstrates Extended Stability
	Press release	Turn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema
	Press release	Turn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours
	Press release	Turn Therapeutics Achieves Major Milestone Toward Improving Vaccine Access
	Press release	Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo

TTRX overview · TTRX earnings · TTRX financials · TTRX KPIs · TTRX ownership · TTRX peers · TTRX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.